## 534 USING EHR DATA TO DYNAMICALLY PREDICT INCIDENCE OF HOSPITAL-ACQUIRED PRESSURE ULCERS

William Padula,<sup>1</sup> Tony Ursitti,<sup>2</sup> Laura Ruth Venable,<sup>2</sup> Adam Ginensky,<sup>2</sup> Mary Beth Makic,<sup>3</sup> Heidi Wald,<sup>3</sup> Manish Mishra,<sup>4</sup> Robert Valuck,<sup>5</sup> Donald Hedeker,<sup>2</sup> Robert Gibbons,<sup>2</sup> David Meltzer<sup>2</sup>. <sup>1</sup>Johns Hopkins Bloomberg School of Public Health, United States; <sup>2</sup>University of Chicago, United States; <sup>3</sup>University of Colorado School of Medicine, United States; <sup>4</sup>Geisel School of Medicine at Dartmouth, United States; <sup>5</sup>University of Colorado Skaggs School of Pharmacy and Pharmaceutical Science, United States

10.1136/bmjqs-2015-IHIabstracts.10

**Background** Hospital-acquired pressure ulcers (HAPUs) are costly to treat and can result in Medicare reimbursement penalties. Statistical models can identify patients at greatest HAPU risk and improve prevention.

**Objectives** To use electronic health record (EHR) data to predict HAPUs among hospitalized patients.

Methods EHR data were obtained from an academic medical center that included hospitalized patients with at least 1 skin examination between 2011–2014. These data contained encounter-level demographic variables, diagnoses, prescription drugs and provider orders. HAPUs were defined by stages III, IV or unstageable pressure ulcers not present-on-admission as a secondary diagnosis, and excluded diagnosis of paraplegia/quadriplegia. Random forests and k-means clustering were applied to reduce the dimensionality of the large dataset. A 2-level mixed-effects logistic regression of patient-encounters evaluated associations between covariates and HAPU incidence (Equation 1).

**Results** The approach produced a sample population of 23,054 patients with 1,549 HAPUs. The mixed-effects model predicted HAPUs with exceptional (99%) accuracy for a rare event (table 1). The greatest odds ratio (OR) of HAPU incidence was among patients diagnosed with spinal cord injury (ICD-9 907.2: OR=247.4; P<0.001). Other high ORs included osteomyelitis (ICD-9 730: OR=27.7, P<0.001), bed confinement (ICD-9 V49.84: OR=31.7, P<0.001), and prescribed topical/subcutaneous enzymes (OR=5.7, P<0.001).

**Conclusions** Early detection of HAPUs is feasible and the results of these statistical predictions can allow providers to better target prevention to specific patients. This model also implicates spinal cord injury as a potential risk-factor for unavoidable HAPUs. Providers may be missing opportunities to co-diagnose spinal cord injury with paraplegia/quadriplegia which could improve hospital performance measures.

Equation 1. Mixed-effects Logistic Regression Model Level-1: Encounter-level Fixed Effects

 $Logit[E(Y_{ij})] = b_0 + \beta_1 Age_{ij} + \beta_2 BradenScore_{ij} + \beta_3 Rx_{ij} + \beta_3 Dx_{ij} + \beta_3 Order_{ij} + \dots + Z_{ij}$ 

Level-2: Patient/Cluster-level Random Effect

$$b_0 = \beta_0 + u_{i0}$$

Where… i: Patient j: Encounter

 Table 1
 Results of 2-level Mixed-effects Logistic Regression and population-average estimates for HAPU incidence by patient-encounter.

Variable	2-Level Mixed-effects Logitistic Regression				Population-average Estimates (GEE)			
	Estimate	Odds Ratio	Standard Error	P-value	Estimate	Odds Ratio	Standard Error	P-value
Intercept	-9.469	0.000	0.331	<0.001	-7.016	0.001	0.175	<0.001
Age	0.049	1.050	0.003	< 0.001	0.040	1.041	0.002	<0.001
Bronchoscopy	0.513	1.671	0.248	0.038	0.408	1.504	0.190	0.032
Culture, Stool	0.514	1.672	0.158	0.001	0.414	1.512	0.123	0.001
Urinalysis Chemistry Screen	0.841	2.319	0.089	<0.001	0.693	2.000	0.073	<0.001
Pre-albumin	0.983	2.674	0.091	<0.001	0.761	2.141	0.067	<0.001
Vancomycin Random Assay	0.959	2.609	0.094	<0.001	0.728	2.071	0.069	<0.001
Culture & Stain, Wound Drainage	0.790	2.203	0.135	<0.001	0.582	1.790	0.098	<0.001
Topical Sulfonamides	1.732	5.653	0.115	<0.001	1.297	3.660	0.078	<0.001
Topical/Mucous Membrane/Subcutaneous Enzymes	3.389	29.622	0.276	< 0.001	2.109	8.236	0.167	< 0.001
Phosphate Replacement	0.260	1.297	0.085	0.002	0.204	1.227	0.068	0.003
Antifu ngal Agent	0.472	1.603	0.094	<0.001	0.385	1.470	0.075	<0.001
Erythropoiesis-stimulating Agent	0.995	2.705	0.134	<0.001	0.768	2.156	0.098	<0.001
ICD-9 V49.84: Bed Confinement	3.457	31.730	0.539	<0.001	2.198	9.003	0.334	<0.001
ICD-9 907.2: Spinal Cord Injury	5.511	247.364	0.500	<0.001	3.814	45.311	0.318	<0.001
ICD-9 730.15: Chronic Osteomyelitis – Pelvic a nd Thigh Regions	3.323	27.746	0.697	<0.001	2.312	10.094	0.474	<0.001
ICD-9 730.18: Chronic Osteomyelitis – Other	3.001	20.099	0.806	<0.001	1.932	6.904	0.516	<0.001
Variance(Intercept)	4.355		0.486					
Log-likelihood	-4737.36							